Wakabayashi T, Yoshida J, Kito A, Inoue I, Kobayashi T, Kageyama N
Gan To Kagaku Ryoho. 1984 Dec;11(12 Pt 2):2729-37.
Ten patients with malignant brain tumor (8 cases with glioblastoma, 2 cases with medulloblastoma) were treated with a new water-soluble nitrosourea, MCNU. Objective tumor regression of tumor (CR & PR) on computerized tomography was observed in four patients (2 complete and 2 partial) after MCNU, chemotherapy showing a response rate of 40%. The major side effects of MCNU were mild or moderate myelosuppression, and some cases also showed gastrointestinal toxicities and impairment of hepatic function. However, all these side effects were mild and transient and soon recovered to normal levels. One patient with glioblastoma multiforme recurrence was treated with a high-dose chemotherapy of MCNU (400 mg) associated with autologous bone marrow transplantation. Myelosuppression began to appear from 15th day of MCNU administration and normalized within 30 days afterwards. These results suggest that MCNU therapy is effective for patients with malignant brain tumors.
10例恶性脑肿瘤患者（8例胶质母细胞瘤，2例髓母细胞瘤）接受了一种新型水溶性亚硝基脲——甲环亚硝脲（MCNU）的治疗。在接受MCNU化疗后，4例患者（2例完全缓解，2例部分缓解）在计算机断层扫描中观察到目标肿瘤缩小（完全缓解和部分缓解），缓解率为40%。MCNU的主要副作用为轻度或中度骨髓抑制，部分病例还表现出胃肠道毒性和肝功能损害。然而，所有这些副作用均较轻且为一过性，很快恢复至正常水平。1例多形性胶质母细胞瘤复发患者接受了与自体骨髓移植相关的高剂量MCNU化疗（400 mg）。骨髓抑制在MCNU给药第15天开始出现，并在随后30天内恢复正常。这些结果表明，MCNU治疗对恶性脑肿瘤患者有效。
